Arcutis’s Phase III AD Win Bodes Well For Soon-To-Report Second Study
Executive Summary
One analyst said efficacy data for roflumilast in INTEGUMENT-1 suggest limited competitiveness against Incyte’s topical JAK inhibitor, Opzelura, while others were more optimistic.
You may also be interested in...
Arcutis’s Zoryve Succeeds In Second Phase III In Atopic Dermatitis
Immuno-dermatology specialist intends to submit the topical roflumilast to the US FDA during the first half of 2023, potentially adding an even larger indication to its approval for psoriasis.
Arcutis Launches Zoryve For Psoriasis As A New Topical In A Growing Category
Zoryve joins Dermavant's Vtama as a new topical drug with a broad label for plaque psoriasis and offers some points of differentiation, including price.
Arcutis Enjoys Seborrheic Dermatitis Win But Experts Itching For Psoriasis Approval
The firm is planning a US NDA filing after its roflumilast formulation succeeded in a pivotal seborrheic dermatitis study but analysts are keener on a ‘make or break’ approval in psoriasis.